

Special Issue

Neuropathic Diseases: From Mechanisms to Novel Therapeutic Approaches

Message from the Guest Editors

Neuropathic pain is caused by lesions or degeneration of the somatosensory system and is a major public health issue in the world. Although the treatment for neuropathic pain remains a great challenge, progress has been made in identifying key molecules and their roles in pain modulation and processing. Thus, the identification of novel molecular and cellular targets for the development of effective and safe therapeutic strategies requires particular attention from the medical community. In this Special Issue, original research articles and reviews are welcome. The purpose of this issue is to advance our understanding of novel neuropathic pain-related molecules and signaling pathways that can be used as therapeutic targets for the treatment of pain. Research areas may include (but not limited to) the following:

- Identification of potential therapeutic targets and pathophysiological mechanisms of neuropathic pain;
- Novel molecules, which are implicated in the pathophysiological changes in somatosensory system.

Dr. Yu-Cheng Ho

Guest Editors

Dr. Yu-Cheng Ho

School of Medicine, College of Medicine, I-Shou University, Kaohsiung City 82445, Taiwan

Dr. Ming Tatt Lee

Faculty of Pharmaceutical Sciences, UCSI University, Kuala Lumpur, Malaysia

Deadline for manuscript submissions

closed (15 May 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/151870

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).